CR20160254A - Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil. - Google Patents

Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil.

Info

Publication number
CR20160254A
CR20160254A CR20160254A CR20160254A CR20160254A CR 20160254 A CR20160254 A CR 20160254A CR 20160254 A CR20160254 A CR 20160254A CR 20160254 A CR20160254 A CR 20160254A CR 20160254 A CR20160254 A CR 20160254A
Authority
CR
Costa Rica
Prior art keywords
bladder
erectile dysfunction
urinary tract
symptoms
compositions
Prior art date
Application number
CR20160254A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Andrew; Klaiber
Daniel David; Souza
Emilie Annie Claudie; Fromentin
Original Assignee
Naturex-Dbs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naturex-Dbs Llc filed Critical Naturex-Dbs Llc
Publication of CR20160254A publication Critical patent/CR20160254A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20160254A 2013-11-11 2014-11-11 Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil. CR20160254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Publications (1)

Publication Number Publication Date
CR20160254A true CR20160254A (es) 2016-08-31

Family

ID=53042226

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160254A CR20160254A (es) 2013-11-11 2014-11-11 Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil.

Country Status (21)

Country Link
US (5) US20160324911A1 (cg-RX-API-DMAC7.html)
EP (2) EP3782634B1 (cg-RX-API-DMAC7.html)
JP (2) JP6966196B2 (cg-RX-API-DMAC7.html)
KR (2) KR102476969B1 (cg-RX-API-DMAC7.html)
CN (2) CN105848663A (cg-RX-API-DMAC7.html)
AU (1) AU2014346415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016010509B1 (cg-RX-API-DMAC7.html)
CA (2) CA3277615A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016001109A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160254A (cg-RX-API-DMAC7.html)
ES (2) ES2980381T3 (cg-RX-API-DMAC7.html)
IL (1) IL245552B (cg-RX-API-DMAC7.html)
MX (1) MX373448B (cg-RX-API-DMAC7.html)
MY (1) MY184225A (cg-RX-API-DMAC7.html)
NZ (1) NZ719268A (cg-RX-API-DMAC7.html)
PH (1) PH12016500780A1 (cg-RX-API-DMAC7.html)
PL (1) PL3068414T3 (cg-RX-API-DMAC7.html)
RU (1) RU2696584C1 (cg-RX-API-DMAC7.html)
SG (2) SG11201603462SA (cg-RX-API-DMAC7.html)
WO (1) WO2015070203A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602941B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2696584C1 (ru) * 2013-11-11 2019-08-05 НАТЮРЕКС-ДиБиЭс ЭлЭлСи Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов
JP6412291B1 (ja) * 2017-01-20 2018-10-24 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
US20200360466A1 (en) * 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
CA3160517A1 (en) * 2019-11-08 2021-05-14 Cj Cheiljedang Corporation A composition for use in reducing an off-taste or off-flavor comprising chlorogenic acid, caffeic acid, and quinic acid
WO2022045846A1 (ko) * 2020-08-31 2022-03-03 건국대학교 글로컬산학협력단 미선나무 추출물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환 치료용 약학적 조성물
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물
WO2025038998A1 (en) * 2023-08-17 2025-02-20 University Of Wyoming Materials and methods for inhibiting, preventing, and dispersing biofilms
CN121985956A (zh) 2023-10-09 2026-05-05 奇华顿股份有限公司 组合物
CN120204245A (zh) * 2024-12-12 2025-06-27 湖北医药学院 连翘苷在制备预防或治疗高尿酸血症的药物中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6231866B1 (en) * 1998-04-30 2001-05-15 Douglas G. Mann Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
AU2005201455A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
JP2008500027A (ja) * 2004-05-03 2008-01-10 ノーザン ライツ フード プロセシング,エルエルシー ベリーオイルおよび製品
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
EP2170352A1 (en) * 2007-06-27 2010-04-07 Coloplast A/S Treatment of urinary tract infections with a mixture of saponin and an antibiotic
CN101095764B (zh) * 2007-07-13 2010-05-19 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
EP2156835A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
WO2011088420A1 (en) 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
CN101999648B (zh) * 2010-10-11 2012-10-31 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
US20130122146A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food
RU2696584C1 (ru) * 2013-11-11 2019-08-05 НАТЮРЕКС-ДиБиЭс ЭлЭлСи Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов

Also Published As

Publication number Publication date
EP3068414A1 (en) 2016-09-21
ES2860773T3 (es) 2021-10-05
CL2016001109A1 (es) 2016-12-02
IL245552A0 (en) 2016-06-30
AU2014346415A1 (en) 2016-05-12
SG10201910781SA (en) 2020-01-30
MX2016005810A (es) 2016-11-18
US12233101B2 (en) 2025-02-25
US20190358282A1 (en) 2019-11-28
CN105848663A (zh) 2016-08-10
JP2020059725A (ja) 2020-04-16
CN116077548A (zh) 2023-05-09
US11291703B2 (en) 2022-04-05
JP2016539183A (ja) 2016-12-15
KR102476969B1 (ko) 2022-12-12
ZA201602941B (en) 2022-05-25
KR20230004886A (ko) 2023-01-06
JP6966196B2 (ja) 2021-11-10
US20180256663A1 (en) 2018-09-13
PH12016500780B1 (en) 2016-06-13
EP3068414A4 (en) 2017-06-07
US10898534B2 (en) 2021-01-26
ES2980381T3 (es) 2024-10-01
US20220175863A1 (en) 2022-06-09
US20200121750A1 (en) 2020-04-23
EP3068414B1 (en) 2020-12-30
KR102745710B1 (ko) 2024-12-20
BR112016010509B1 (pt) 2021-08-17
AU2014346415B2 (en) 2020-04-23
WO2015070203A9 (en) 2016-01-14
US11045511B2 (en) 2021-06-29
PH12016500780A1 (en) 2016-06-13
CA2928631A1 (en) 2015-05-14
CA2928631C (en) 2025-08-12
PL3068414T3 (pl) 2021-08-30
WO2015070203A1 (en) 2015-05-14
MY184225A (en) 2021-03-28
NZ719268A (en) 2021-07-30
RU2016122062A (ru) 2017-12-19
US20160324911A1 (en) 2016-11-10
RU2696584C1 (ru) 2019-08-05
MX373448B (es) 2020-06-11
BR112016010509A2 (pt) 2017-08-08
EP3782634B1 (en) 2024-03-20
KR20160079884A (ko) 2016-07-06
CA3277615A1 (en) 2025-10-30
SG11201603462SA (en) 2016-05-30
JP7083330B2 (ja) 2022-06-10
IL245552B (en) 2020-07-30
EP3782634A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
MX2016005810A (es) Composiciones y metodos utiles en el tratamiento de sintomas del tracto urinario inferior, hiperplasia prostatica benigna, disfuncion erectil.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
BR112021021165A2 (pt) Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos
PH12020551427A1 (en) Epinephrine spray formulations
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
PH12018502429A1 (en) Antibody molecules for cancer treatment
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12016502447A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
AR102924A1 (es) Composiciones anticancerosas
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
GB2539160A (en) Therapeutic composition
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
ZA202201070B (en) Focal treatment of prostate cancer
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
MX2021014729A (es) Metodos y composiciones para tratar enfermedades autoinmunitarias.
RU2011138818A (ru) Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
WO2012135856A3 (en) Very low dose vinorelbine for treatment of cancer